Sector News

Struggling GlobeImmune brings in financial advisers as options dwindle

August 14, 2015
Life sciences
Not long after a mid-stage trial failure blasted its stock value and forced the company to lay off most of its staff, a troubled GlobeImmune has brought in Cantor Fitzgerald to advise the biotech on its “strategic options”–which may signal that a fire sale is in the offing.
 
GlobeImmune CEO Timothy Rodell had tried to make the best of things when he fingered signs of biologic activity among a handful of patients given the hep B vaccine GS-4774 in a Phase II trial. But the big takeaway was that the Louisville, CO-based company’s lead program had flunked out when given a chance to establish proof-of-concept data among the 178 patients in the study.
 
As a result of that failure, GlobeImmune’s shares were shattered and the company’s market cap sits at a tiny $15 million–a bite-sized target for anyone interested in the company.
 
Gilead in-licensed the hep B program back in 2011 and the biotech has a second Phase II trial underway as well. Celgene ($CELG), meanwhile, stepped in early a few days ago to pick up its option on GI-6207, which targets cancer cells that express a carcinoembryonic antigen.
 
Celgene paid only $1.9 million for the accelerated option, with potential royalties attached, gaining a therapy that’s now in a 34-patient Phase II study at the NCI, where investigators are studying its impact on calcitonin levels–a biomarker for recurrent medullary thyroid cancer.
 
The biotech industry has enjoyed a three-year romp on Wall Street, but weak companies with small pipelines are at risk of a savage beating at the hands of investors when things go sour. GlobeImmune only raised about $15 million when it sold a batch of IPO shares at $10 each–well under its range–last summer. The stock was trading at $2.60 this morning.
 
By John Carroll
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach